Promising Therapeutic Impact of Immune Checkpoint Inhibitors in Type II Endometrial Cancer Patients with Deficient Mismatch Repair Status

Type II endometrial cancer (EC) is responsible for most endometrial cancer-related deaths due to its aggressive nature, late-stage detection, and high tolerance to standard therapies. Thus, novel treatment strategies for type II EC are imperative. For patients with mismatch repair-deficient (dMMR) t...

Descripción completa

Detalles Bibliográficos
Autores principales: Sawada, Kiyoka, Nakayama, Kentaro, Razia, Sultana, Yamashita, Hitomi, Ishibashi, Tomoka, Ishikawa, Masako, Kanno, Kosuke, Sato, Seiya, Nakayama, Satoru, Otsuki, Yoshiro, Kyo, Satoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137870/
https://www.ncbi.nlm.nih.gov/pubmed/37107907
http://dx.doi.org/10.3390/healthcare11081073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137870/
https://www.ncbi.nlm.nih.gov/pubmed/37107907
http://dx.doi.org/10.3390/healthcare11081073

Ejemplares similares